Advertisement

Tumor Biology

, Volume 34, Issue 5, pp 2899–2907 | Cite as

Lack of association of genetic polymorphisms of angiotensin converting enzyme 1 and angiotensin II type 1 receptor with breast cancer risk in Iranian population

  • Soha Namazi
  • Ahmad Monabati
  • Shirin Ardeshir-Rouhani-FardEmail author
  • Negar Azarpira
Research Article

Abstract

We aimed to investigate the association of insertion/deletion (I/D) and A1166C polymorphisms of angiotensin I converting enzyme 1 and angiotensin II type 1 receptor genes, respectively and their combination on breast cancer risk in an Iranian population. A case–control study (70 cases, 70 controls) was performed on an Iranian population. The I/D and A1166C polymorphisms were analyzed by polymerase chain reaction (PCR) and restriction fragment length polymorphism PCR, respectively. The results revealed no significant difference between cases and controls in I/D (p = 0.14) and A1166C (p = 0.94) polymorphisms after adjustment for breast cancer known risk factors. In combined genotype analysis, considering DD and AA genotypes as low-risk genotypes, women with one and two high-risk genotypes (one high-risk genotype: adjusted odds ratio (OR), 1.24; two high-risk genotypes: adjusted OR, 1.97) were at higher risk for breast cancer. Also, the highest risk for breast cancer was seen in a subgroup of postmenopausal women carriers of two high-risk genotypes (adjusted OR, 2.41). In conclusion, I/D and A1166C polymorphisms are not significantly associated with breast cancer risk in the Iranian population; however, the combination of these two polymorphisms seems to have a synergic effect on the risk of breast cancer particularly in postmenopausal women, which may deserve consideration in large-scale case–control studies.

Keywords

Renin–angiotensin system Risk factor Menopausal status Synergic effect Polymorphism 

Notes

Acknowledgments

We would like to express our gratitude to Dr. Talei at Shahid Faghihi Hospital, Shiraz, Iran for providing samples and clinical information. We also greatly thank Ms. Valibeigi for her technical assistance in genotyping the samples. We would like to acknowledge the Clinical Research Development Center for giving helpful comments on data analysis.

Conflicts of interest

None

References

  1. 1.
    Harirchi I, Kolahdoozan S, Karbakhsh M, Chegini N, Mohseni SM, Montazeri A, et al. Twenty years of breast cancer in Iran: downstaging without a formal screening program. Ann Oncol. 2011;22:93–7.CrossRefPubMedGoogle Scholar
  2. 2.
    Paul M, Mehr AP, Kreutz R. Physiology of local renin–angiotensin systems. Physiol Rev. 2006;86:747–803.CrossRefPubMedGoogle Scholar
  3. 3.
    Ager EI, Neo J, Christophi C. The renin-angiotensin system and malignancy. Carcinogenesis. 2008;29:1675–84.CrossRefPubMedGoogle Scholar
  4. 4.
    Rosenthal T, Gavras I. Angiotensin inhibition and malignancies: a review. J Hum Hypertens. 2009;23:623–35.CrossRefPubMedGoogle Scholar
  5. 5.
    Sayed-Tabatabaei FA, Oostra BA, Isaacs A, Van Duijn CM, Witteman JCM. ACE polymorphisms. Circ Res. 2006;98:1123–33.CrossRefPubMedGoogle Scholar
  6. 6.
    Rigat B, Hubert C, Alhenc-Gelas F, Cambien F, Corvol P, Soubrier F. An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest. 1990;86:1343–6.PubMedCentralCrossRefPubMedGoogle Scholar
  7. 7.
    Haiman CA, Henderson SO, Bretsky P, Kolonel LN, Henderson BE. Genetic variation in angiotensin I-converting enzyme (ACE) and breast cancer risk: the multiethnic cohort. Cancer Res. 2003;63:6984–7.PubMedGoogle Scholar
  8. 8.
    Alves Corrêa SA, Ribeiro de Noronha SM, Nogueira-de-Souza NC, Valleta de Carvalho C, Massad Costa AM, Juvenal Linhares J et al. Association between the angiotensin-converting enzyme (insertion/deletion) and angiotensin II type 1 receptor (A1166C) polymorphisms and breast cancer among Brazilian women. J Renin Angiotensin Aldosterone Syst. 2009;10:51–8Google Scholar
  9. 9.
    Koh WP, Yuan JM, Sun CL, Van den Berg D, Seow A, Lee HP, et al. Angiotensin I-converting enzyme (ACE) gene polymorphism and breast cancer risk among Chinese women in Singapore. Cancer Res. 2003;63:573–8.PubMedGoogle Scholar
  10. 10.
    González-Zuloeta Ladd AM, Vasquez AA, Sayed-Tabatabaei FA, Coebergh JW, Hofman A, Njajou O, et al. Angiotensin-converting enzyme gene insertion/deletion polymorphism and breast cancer risk. Cancer Epidemiol Biomarkers Prev. 2005;14:2143–6.CrossRefPubMedGoogle Scholar
  11. 11.
    Van Der Knaap R, Siemes C, Coebergh JW, Van Duijn CM, Hofman A, Stricker BHC. Renin–angiotensin system inhibitors, angiotensin I-converting enzyme gene insertion/deletion polymorphism, and cancer: The Rotterdam study. Cancer. 2008;112:748–57.CrossRefPubMedGoogle Scholar
  12. 12.
    Oro C, Qian H, Thomas WG. Type 1 angiotensin receptor pharmacology: signaling beyond G proteins. Pharmacol Ther. 2007;113:210–26.CrossRefPubMedGoogle Scholar
  13. 13.
    Fischer M, Baessler A, Schunkert H. Renin angiotensin system and gender differences in the cardiovascular system. Cardiovasc Res. 2002;53:672–7.CrossRefPubMedGoogle Scholar
  14. 14.
    Wassmann S, Nickenig G. Pathophysiological regulation of the AT1-receptor and implications for vascular disease. J Hypertens. 2006;24:S15–21.CrossRefGoogle Scholar
  15. 15.
    Komukai K, Mochizuki S, Yoshimura M. Gender and the renin–angiotensin–aldosterone system. Fundam Clin Pharmacol. 2010;24:687–98.CrossRefPubMedGoogle Scholar
  16. 16.
    Afonso N. Women at high risk for breast cancer—what the primary care provider needs to know. J Am Board Fam Med. 2009;22:43–50.CrossRefPubMedGoogle Scholar
  17. 17.
    Lorincz A, Sukumar S. Molecular links between obesity and breast cancer. Endocr Relat Cancer. 2006;13:279–92.CrossRefPubMedGoogle Scholar
  18. 18.
    Bianchini F, Kaaks R, Vainio H. Overweight, obesity, and cancer risk. Lancet Oncol. 2002;3:565–74.CrossRefPubMedGoogle Scholar
  19. 19.
    Namazi S, Monabati A, Ardeshir-Rouhani-Fard S, Azarpira N. Association of angiotensin I converting enzyme (insertion/deletion) and angiotensin II type 1 receptor (A1166C) polymorphisms with breast cancer prognostic factors in iranian population. Mol Carcinog. 2010;49:1022–30.CrossRefPubMedGoogle Scholar
  20. 20.
    Koh WP, Yuan JM, Van Den Berg D, Lee HP, Yu MC. Polymorphisms in angiotensin II type 1 receptor and angiotensin I-converting enzyme genes and breast cancer risk among Chinese women in Singapore. Carcinogenesis. 2005;26:459–64.CrossRefPubMedGoogle Scholar
  21. 21.
    Li CI, Malone KE, Weiss NS, Boudreau DM, Cushing-Haugen KL, Daling JR. Relation between use of antihypertensive medications and risk of breast carcinoma among women ages 65–79 years. Cancer. 2003;98:1504–13.CrossRefPubMedGoogle Scholar
  22. 22.
    Welsh ML, Buist DSM, Aiello Bowles EJ, Anderson ML, Elmore JG, Li CI. Population-based estimates of the relation between breast cancer risk, tumor subtype, and family history. Breast Cancer Res Treat. 2009;114:549–58.PubMedCentralCrossRefPubMedGoogle Scholar
  23. 23.
    Dumitrescu RG, Cotarla I. Understanding breast cancer risk—where do we stand in 2005? J Cell Mol Med. 2005;9:208–21.CrossRefPubMedGoogle Scholar
  24. 24.
    Pike MC, Spicer DV, Dahmoush L, Press MF. Estrogens, progestogens, normal breast cell proliferation, and breast cancer risk. Epidemiol Rev. 1993;15:17–30.PubMedGoogle Scholar
  25. 25.
    Biller H, Zissel G, Ruprecth B, Nauck M, Busse Grawitz A, Müller-Quernheim J. Genotype-corrected reference values for serum angiotensin-converting enzyme. Eur Respir J. 2006;28:1085–90.CrossRefPubMedGoogle Scholar
  26. 26.
    Tiret L, Rigat B, Visvikis S, Breda C, Corvol P, Cambien F, et al. Evidence, from combined segregation and linkage analysis, that a variant of the angiotensin I-converting enzyme (ACE) gene controls plasma ACE levels. Am J Hum Genet. 1992;51:197–205.PubMedCentralPubMedGoogle Scholar
  27. 27.
    Castellon R, Hamdi HK. Demystifying the ACE polymorphism: from genetics to biology. Curr Pharm Des. 2007;13:1191–8.CrossRefPubMedGoogle Scholar
  28. 28.
    Baudin B. New aspects on angiotensin-converting enzyme: from gene to disease. Clin Chem Lab Med. 2002;40:256–65.CrossRefPubMedGoogle Scholar
  29. 29.
    Ceolotto G, Papparella I, Bortoluzzi A, Strapazzon G, Ragazzo F, Bratti P, et al. Interplay between miR-155, AT1R A1166C polymorphism, and AT1R expression in young untreated hypertensives. Am J Hypertens. 2011;24:241–6.CrossRefPubMedGoogle Scholar
  30. 30.
    Deshayes F, Nahmias C. Angiotensin receptors: a new role in cancer. Trends Endocrinol Metab. 2005;16:293–9.CrossRefPubMedGoogle Scholar
  31. 31.
    Rhodes D, Ateeq B, Cao Q, Tomlins S, Mehra R, Laxman B, et al. AGTR1 overexpression defines a subset of breast cancer and confers sensitivity to losartan, an AGTR1 antagonist. Proc Natl Acad Sci U S A. 2009;106:10284–9.PubMedCentralCrossRefPubMedGoogle Scholar
  32. 32.
    Tiret L, Bonnardeaux A, Poirier O, Ricard S, Marques-Vidal P, Evans A, et al. Synergistic effects of angiotensin-converting enzyme and angiotensin-II type 1 receptor gene polymorphisms on risk of myocardial infarction. Lancet. 1994;344:910–3.CrossRefPubMedGoogle Scholar
  33. 33.
    Fukazawa R, Sonobe T, Hamamoto K, Hamaoka K, Sakata K, Asano T, et al. Possible synergic effect of angiotensin-I converting enzyme gene insertion/deletion polymorphism and angiotensin-II type-1 receptor 1166A/C gene polymorphism on ischemic heart disease in patients with Kawasaki disease. Pediatr Res. 2004;56:597–601.CrossRefPubMedGoogle Scholar
  34. 34.
    Szolnoki Z, Maasz A, Magyari L, Horvatovich K, Farago B, Somogyvari F, et al. Coexistence of angiotensin II type-1 receptor A1166C and angiotensin-converting enzyme D/D polymorphism suggests susceptibility for small-vessel-associated ischemic stroke. Neuromolecular Med. 2006;8:353–60.CrossRefPubMedGoogle Scholar
  35. 35.
    Álvarez R, Reguero JR, Batalla A, Iglesias-Cubero G, Cortina A, Álvarez V, et al. Angiotensin-converting enzyme and angiotensin II receptor 1 polymorphisms: association with early coronary disease. Cardiovasc Res. 1998;40:375–9.CrossRefPubMedGoogle Scholar
  36. 36.
    Burger HG. Physiology and endocrinology of the menopause. Medicine (Baltimore). 2006;34:27–30.CrossRefGoogle Scholar
  37. 37.
    Dean SA, Tan J, O'Brien ER, Leenen FHH. 17β-Estradiol downregulates tissue angiotensin-converting enzyme and ANG II type 1 receptor in female rats. Am J Physiol Regul Integr Comp Physiol. 2005;288:R759–66.CrossRefPubMedGoogle Scholar
  38. 38.
    Dubey RK, Oparil S, Imthurn B, Jackson EK. Sex hormones and hypertension. Cardiovasc Res. 2002;53:688–708.CrossRefPubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2013

Authors and Affiliations

  • Soha Namazi
    • 1
  • Ahmad Monabati
    • 2
  • Shirin Ardeshir-Rouhani-Fard
    • 1
    • 4
    Email author
  • Negar Azarpira
    • 3
  1. 1.Department of Clinical Pharmacy, School of PharmacyShiraz University of Medical SciencesShirazIran
  2. 2.Department of Pathology, School of MedicineShiraz University of Medical SciencesShirazIran
  3. 3.Organ Transplant Research Center, Namazi HospitalShiraz University of Medical SciencesShirazIran
  4. 4.Department of Clinical Pharmacy, School of PharmacyShiraz University of Medical SciencesShirazIran

Personalised recommendations